Mercato chiuso -
Altri mercati azionari
|
Variaz. 5gg | Var. 1 gen. | ||
158,4 USD | +3,30% | +8,14% | -19,73% |
23/04 | ZOETIS INC. : Barclays ancora positivo | ZM |
23/04 | ZOETIS INC. : Jefferies & Co. mantiene la raccomandazione Neutral | ZM |
Attività
- animali domestici (64,4%): cani e gatti (94,9% delle vendite nette) e cavalli (5,1%);
- bestiame (34,5%): bovini (51,6% delle vendite), suini (20,2%), pollame (17,1%), pesci (7,6%) e altro (3,5%);
- altro (1,1%).
Le vendite nette si suddividono per famiglia di prodotti in parassiticidi (23%), vaccini (21,3%), prodotti dermatologici (16,4%), antinfettivi (13,4%), additivi alimentari medici (4,5%), prodotti diagnostici (4,4%) e altro (17%).
Alla fine del 2022, il Gruppo avrà 29 siti di produzione in tutto il mondo.
Gli Stati Uniti rappresentano il 53,4% delle vendite nette.
Numero di dipendenti: 14 100
Vendite per attività
USD in Milioni | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
Parasiticides
22,8
%
| 1 860 | 23,0 % | 1 947 | 22,8 % | +4,68% |
Vaccines
20,7
%
| 1 718 | 21,3 % | 1 771 | 20,7 % | +3,08% |
Dermatology
16,7
%
| 1 329 | 16,4 % | 1 427 | 16,7 % | +7,37% |
Other Pharmaceuticals
15,0
%
| 1 043 | 12,9 % | 1 280 | 15,0 % | +22,72% |
Anti-infectives
12,4
%
| 1 081 | 13,4 % | 1 057 | 12,4 % | -2,22% |
Animal Health Diagnostics
4,4
%
| 353 | 4,4 % | 376 | 4,4 % | +6,52% |
Medicated Feed Additives
4,1
%
| 360 | 4,5 % | 354 | 4,1 % | -1,67% |
Other Non-pharmaceuticals
3,0
%
| 250 | 3,1 % | 254 | 3,0 % | +1,60% |
Contract Manufacturing and Human Health
0,9
%
| 86 | 1,1 % | 78 | 0,9 % | -9,30% |
Vendite per regione
USD in Milioni | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
United States
53,3
%
| 4 313 | 53,4 % | 4 555 | 53,3 % | +5,61% |
Other Emerging Markets
9,2
%
| 758 | 9,4 % | 784 | 9,2 % | +3,43% |
Other Developed Markets
6,0
%
| 468 | 5,8 % | 512 | 6,0 % | +9,40% |
Brazil
4,6
%
| 330 | 4,1 % | 393 | 4,6 % | +19,09% |
Australia
3,8
%
| 289 | 3,6 % | 323 | 3,8 % | +11,76% |
China
3,7
%
| 382 | 4,7 % | 320 | 3,7 % | -16,23% |
United Kingdom
3,2
%
| 235 | 2,9 % | 277 | 3,2 % | +17,87% |
Canada
3,0
%
| 238 | 2,9 % | 255 | 3,0 % | +7,14% |
Germany
2,4
%
| 176 | 2,2 % | 202 | 2,4 % | +14,77% |
Mexico
1,9
%
| 136 | 1,7 % | 162 | 1,9 % | +19,12% |
Japan
1,8
%
| 173 | 2,1 % | 158 | 1,8 % | -8,67% |
France
1,7
%
| 126 | 1,6 % | 142 | 1,7 % | +12,70% |
Chile
1,6
%
| 141 | 1,7 % | 140 | 1,6 % | -0,71% |
Spain
1,4
%
| 118 | 1,5 % | 122 | 1,4 % | +3,39% |
Italy
1,4
%
| 111 | 1,4 % | 121 | 1,4 % | +9,01% |
Global
0,9
%
| 86 | 1,1 % | 78 | 0,9 % | -9,30% |
Dirigenti
Dirigenti | Titolo | Età | Da |
---|---|---|---|
Kristin Peck
CEO | Chief Executive Officer | 52 | 01/01/12 |
Wetteny Joseph
DFI | Director of Finance/CFO | 52 | 01/06/21 |
Mike McFarland
CTO | Chief Tech/Sci/R&D Officer | - | 01/01/11 |
Robert Polzer
CTO | Chief Tech/Sci/R&D Officer | 56 | 01/01/15 |
Wafaa Mamilli
CTO | Chief Tech/Sci/R&D Officer | 56 | 01/01/20 |
Steven Frank
IRC | Investor Relations Contact | - | 01/03/15 |
William Dorsey
PRN | Corporate Officer/Principal | - | - |
Ester Banque
PRN | Corporate Officer/Principal | - | 10/07/23 |
Abhay Nayak
PRN | Corporate Officer/Principal | - | - |
Roxanne Lagano
HRO | Human Resources Officer | 59 | 01/10/12 |
Amministratori
Amministratori | Titolo | Età | Da |
---|---|---|---|
Chairman | 71 | 01/01/13 | |
Louise Parent
BRD | Director/Board Member | 73 | 01/08/13 |
Robert Scully
BRD | Director/Board Member | 74 | 01/06/13 |
Kristin Peck
CEO | Chief Executive Officer | 52 | 01/01/12 |
Paul Bisaro
BRD | Director/Board Member | 63 | 01/05/15 |
Frank D'Amelio
BRD | Director/Board Member | 66 | 01/07/12 |
Sanjay Khosla
BRD | Director/Board Member | 71 | 01/06/13 |
Gregory Norden
BRD | Director/Board Member | 66 | 01/01/13 |
Director/Board Member | 55 | 25/07/22 | |
Willie Reed
BRD | Director/Board Member | 69 | 04/03/14 |
Classe di azioni
Voto | Quantità | Flottante | Autocontrollo | Flottante totale | |
---|---|---|---|---|---|
Azione A | 1 | 500 471 090 | 455 877 565 ( 91,09 %) | 43 523 885 ( 8,697 %) | 91,09 % |
Coordinate società
Società del gruppo
Nome | Categoria e settore |
---|---|
Pharmaq AS
Pharmaq AS Pharmaceuticals: MajorHealth Technology PHARMAQ AS operates as a veterinary pharmaceutical company. It provides health products to the global aquaculture industry. The company was founded on July 23, 2004 and is headquartered in Overhalla, Norway. |
Pharmaceuticals: Major
|
Zoetis India Ltd.
Zoetis India Ltd. Pharmaceuticals: MajorHealth Technology Founded in 2007, Zoetis India Ltd. is a subsidiary of Zoetis, Inc. that manufactures vaccines and injectable biologic medicines. The private company is based in Mumbai, India. |
Pharmaceuticals: Major
|
Zoetis Treasury Center BV
| |
Zoetis Belgium SA
Zoetis Belgium SA BiotechnologyHealth Technology Part of Zoetis, Inc., Zoetis Belgium SA is a Belgian company that manufactures animal vaccines and prescription medicines. The private company is based in Louvain-La-Neuve, Belgium. |
Biotechnology
|
Zoetis Singapore Pte Ltd.
| |
Zoetis Vietnam LLC
Zoetis Vietnam LLC Pharmaceuticals: MajorHealth Technology Zoetis Vietnam LLC engages in the distribution of medicine and vaccinations for pets and livestocks. The company was founded on August 16, 2013 and is headquartered in Ho Chi Minh City, Vietnam. |
Pharmaceuticals: Major
|
Zoetis Pharmaceutical Research Pvt Ltd.
| |
Zoetis Korea Ltd.
Zoetis Korea Ltd. Pharmaceuticals: MajorHealth Technology Part of Zoetis, Inc., Zoetis Korea Ltd. is a South Korean company that manufactures veterinary medicinal preparations. The private company is located in South Korea. |
Pharmaceuticals: Major
|
Pharmaq Vietnam Co. Ltd.
|
Settore
Vendite per attività
Vendite per regione
Revisioni EPS
Variaz. 1 gen. | Capi. | |
---|---|---|
-19,73% | 72,39 Mrd | |
-11,01% | 6,54 Mrd | |
+15,88% | 3,43 Mrd | |
-0,68% | 1,4 Mrd | |
-17,27% | 1,34 Mrd | |
-2,73% | 1,26 Mrd | |
-28,16% | 1,2 Mrd | |
-14,67% | 1,12 Mrd | |
-5,37% | 990 Mln | |
-24,06% | 805 Mln |
- Borsa valori
- Azioni
- Azione ZTS
- Società Zoetis Inc.